Targeting a specific protein to treat myelodysplastic syndrome
Therapeutic targeting of IRAK4 in MDS
This study is looking at how a protein called IRAK4 affects myelodysplastic syndrome (MDS) and aims to find ways to block its harmful forms to help improve treatment options for people with MDS and similar conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-10914168 on NIH RePORTER |
What this research studies
This research investigates the role of a protein called IRAK4 in myelodysplastic syndrome (MDS), a condition that can lead to acute myeloid leukemia (AML). The study focuses on how mutations in splicing factors affect the expression of active IRAK4 isoforms, which are linked to poor patient outcomes. By inhibiting these active forms of IRAK4, the research aims to reduce leukemic growth both in laboratory settings and in animal models. This approach could lead to new therapeutic strategies for patients with MDS and related conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with myelodysplastic syndrome or acute myeloid leukemia, particularly those with specific mutations in splicing factors.
Not a fit: Patients without myelodysplastic syndrome or acute myeloid leukemia, or those whose conditions are unrelated to IRAK4 signaling, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new targeted therapy for patients with myelodysplastic syndrome and acute myeloid leukemia.
How similar studies have performed: Other research has shown promising results in targeting IRAK4 in similar contexts, indicating that this approach may be effective.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Verma, Amit K. — Albert Einstein College of Medicine
- Study coordinator: Verma, Amit K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.